Respirerx Pharmaceuticals INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
RespireRx Pharmaceuticals issues an open letter to stakeholders summarizing the macro-environment, challenges, accomplishments, disappointments, and plans for 2025.
Respirerx Pharmaceuticals has amended the terms of its Series I and Series J preferred stock, impacting dividend payouts, voting rights, and liquidation preferences.
RespireRx Pharmaceuticals has engaged Alien Technology Transfer to assist with securing NIH funding for its GABAkines program, focusing on Phase II grant applications.
RespireRx Pharmaceuticals has engaged Alien Technology Transfer for assistance in securing NIH grants for its GABAkines program, while also facing a potential downgrade in its trading market due to disclosure issues.
RespireRx Pharmaceuticals has received a $1.8 million grant from the Department of Defense to fund a Phase 2 clinical trial of its drug CX1739 for improving bladder function in patients with spinal cord injury.
RespireRx Pharmaceuticals has entered into a purchase agreement for a $100,000 loan and issued warrants to purchase 33,333,333 shares of common stock to Dariusz Nasiek, a member of the company's board of directors, and Sara Nasiek.
RespireRx Pharmaceuticals has entered into debt settlement agreements, replacing old notes with new convertible notes totaling $180,000.
RespireRx Pharmaceuticals has appointed Dr. Dariusz Nasiek, an experienced anesthesiologist, to its Board of Directors, effective January 18, 2024.